BioSpace News Archive

Bio-Techne Corporation announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50 million, of which the first $20 million was funded at closing.

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD)

Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team. Brian Lestini, MD, PhD, has joined the company

- NT-300 reduced progression to severe COVID-19 disease by 85% - Romark is working with FDA and plans to seek Emergency Use Authorization in the U.S.

Noxopharm Files Septic Shock Treatment Patent for Veyonda ® New indication doubles the commercial opportunity

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, plans to announce its financial results for the quarter ended March 31, 2021 before the market opens on Wednesday, May 5, 2021, and will host a conference call at 8:30 am ET that day to discuss those results.

Unaudited Financial Results Include Revenue Growth of 133% for Biotricity, Inc.

The Infusion Nurses Society has included the international Aseptic Non Touch Technique framework as a dedicated standard in its recently published 2021 Infusion Therapy Standards of Practice.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the dosing of the first cancer patient with agenT-797, an allogeneic iNKT cell therapy, in a Phase 1 clinical trial through its subsidiary, AgenTus Therapeutics.